Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
Public ClinicalTrials.gov record NCT02273960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)
Study identification
- NCT ID
- NCT02273960
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- BMS-986004 75 mg IV Drug
- BMS-986004 225 mg IV Drug
- BMS-986004 675 mg IV Drug
- BMS-986004 1500 mg IV Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2014
- Primary completion
- Jan 21, 2018
- Completion
- Jan 21, 2018
- Last update posted
- Jul 15, 2019
2014 – 2018
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ. Of Southern Calif. /Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Columbus Regional Research Institute | Columbus | Georgia | 31904 | — |
| Mass General Hospital | Boston | Massachusetts | 02114 | — |
| Rutgers- Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02273960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02273960 live on ClinicalTrials.gov.